Saccharomyces boulardii is one of the most researched probiotics for gut health, yet confusion surrounds which brands deliver the specific strain shown in clinical trials. The designation CNCM I-745 refers to the precise strain used in the majority of high-quality human studies on traveler’s diarrhea, antibiotic-associated diarrhea, and inflammatory bowel conditions.
Most consumers assume any “S. boulardii” product is equivalent. This assumption can lead to disappointing results. Strain specificity matters because different isolates vary in survivability, toxin-binding capacity, and interaction with the human microbiome.
Understanding the CNCM I-745 Strain
CNCM I-745 is the proprietary strain originally isolated in the 1920s and deposited in the Collection Nationale de Cultures de Microorganismes in France. It has been studied in over 100 randomized controlled trials. This strain demonstrates unique properties including the secretion of proteases that degrade bacterial toxins, stimulation of intestinal brush-border enzymes, and modulation of pro- and anti-inflammatory cytokines.
Research shows CNCM I-745 survives gastric acid and bile exceptionally well, reaches the colon in viable concentrations, and does not permanently colonize the gut—making it safe for short- and long-term use. When a label simply states “Saccharomyces boulardii” without the CNCM I-745 identifier, you cannot be certain you are receiving the clinically validated isolate.
Popular Brands: Which Actually Use CNCM I-745?
Several well-known brands clearly state they contain the CNCM I-745 strain. Florastor is the most recognizable; every capsule and sachet uses the exact CNCM I-745 strain at a guaranteed 250 mg (5 billion CFU) dose. Other reputable lines that list CNCM I-745 include certain formulations from Biocodex, the original patent holder, and select professional brands such as Klaire Labs Saccharomyces boulardii and Thorne Saccharomyces boulardii.
Conversely, many budget and generic probiotic powders or capsules use generic S. boulardii strains sourced from baker’s yeast. These products may list impressive CFU counts yet lack the published data supporting toxin neutralization and immune modulation seen with CNCM I-745. Always check the supplement facts panel or certificate of analysis for the specific strain designation.
Common Mistakes Consumers Make
The biggest error is equating CFU count with efficacy. A product boasting 10 billion CFU of an uncharacterized S. boulardii may underperform compared with 5 billion CFU of CNCM I-745. Another frequent mistake is assuming all yeast-based probiotics are interchangeable; some strains produce unwanted metabolites or fail to survive manufacturing and storage.
Storage misconceptions also abound. While CNCM I-745 is relatively stable at room temperature, excessive heat or moisture can reduce viability. Consumers often store products near stoves or in humid bathrooms, unknowingly lowering the active dose by the time they consume it.
Finally, many combine S. boulardii with antibiotics without timing doses correctly. Taking both at the exact same hour can reduce the yeast’s survival. Spacing by two hours is the evidence-based recommendation supported by pharmacokinetic data.
What the Research Actually Says
Meta-analyses confirm CNCM I-745 reduces the risk of antibiotic-associated diarrhea by approximately 57 % and shortens duration of acute infectious diarrhea by nearly 24 hours. In children, it significantly lowers the incidence of traveler’s diarrhea when taken prophylactically.
Emerging studies explore its role in maintaining remission in Crohn’s disease and ulcerative colitis, showing reduced fecal calprotectin and improved intestinal barrier function. CNCM I-745 also appears to enhance the effectiveness of certain anti-inflammatory protocols by lowering systemic markers such as C-reactive protein.
Importantly, the strain supports mitochondrial efficiency within enterocytes, helping restore energy production in damaged gut lining cells. This cellular renewal mechanism explains why many users report reduced bloating and improved nutrient absorption beyond what generic probiotics deliver.
Recent investigations link gut yeast balance to leptin sensitivity and GLP-1 signaling. While S. boulardii is not a weight-loss miracle, a healthy microbiome containing CNCM I-745 may support the metabolic reset many seek after completing protocols like the 30-week tirzepatide reset or aggressive loss phases that emphasize nutrient density and lectin avoidance.
Practical Guide: Choosing and Using S. Boulardii
Look for “Saccharomyces boulardii CNCM I-745” or “S. boulardii DBVPG 6763” (an equivalent designation) on the label. Choose products that guarantee potency through end of shelf life rather than at manufacture. Refrigeration is optional but beneficial in warm climates.
For acute diarrhea, most research protocols use 250–500 mg (5–10 billion CFU) daily for 5–14 days. For ongoing gut support or during antibiotic courses, 250 mg once or twice daily is common. Those following low-carb or lectin-limited eating patterns often add CNCM I-745 during the maintenance phase to stabilize the microbiome after dietary shifts that can temporarily disrupt bacterial balance.
Combine with a diverse, nutrient-dense diet rich in cruciferous vegetables such as bok choy to feed beneficial microbes while the yeast modulates inflammation. Avoid taking it simultaneously with antifungals unless directed by a clinician.
Conclusion
Not all S. boulardii brands are created equal. Choosing products that explicitly use the CNCM I-745 strain ensures you receive the isolate backed by decades of clinical evidence rather than an unknown variant. By avoiding common pitfalls around dosing, storage, and timing, you can harness this resilient probiotic to support gut integrity, immune balance, and potentially aid broader metabolic goals. Next time you reach for a yeast probiotic, take a moment to confirm the strain—your microbiome will thank you.